Use of recombinant human bone morphogenetic protein 2 for mandible reconstruction

Shaun Desai, Alan Sclaroff, Brian Nussenbaum

Research output: Contribution to journalArticle

Abstract

Background: Microvascular osseous free tissue transfer is the standard of care for reconstructing significant mandibulectomy defects; however, this procedure can carry a significant rate of morbidity. Objectives: To describe the use of recombinant human bone morphogenetic protein 2 (rhBMP-2) as an option for segmental or near-complete rim mandibulectomy defects in a select group of patients, precluding the need for free tissue transfer. Methods: A retrospective review was performed of 6 patients who had undergone repair of a mandible defect using rhBMP-2 with beta-tricalcium phosphate matrix or a cadaveric bone graft at a single tertiary care institution. The defects resulted from resection of benign neoplasms or from previous trauma. Reconstruction success was defined as no hardware problems, healing without infection, no need for further surgical procedures, and imaging evidence of healing and union without resorption. The median follow-up period was 37.5 months (range, 12-51 months). Results: Five of 6 patients underwent successful restoration of the mandibulectomy defect. One patient with a compromised immune system developed a significant postoperative wound infection requiring further reconstructive surgery. Conclusion: The use of an rhBMP-2-based reconstructive approach is a feasible option for segmental or nearcomplete rim mandibulectomy defects in a select group of patients. Level of Evidence: 4.

Original languageEnglish (US)
Pages (from-to)204-209
Number of pages6
JournalJAMA Facial Plastic Surgery
Volume15
Issue number3
DOIs
StatePublished - May 2013
Externally publishedYes

Fingerprint

Mandible
Reconstructive Surgical Procedures
Surgical Wound Infection
Tertiary Healthcare
Standard of Care
Immune System
recombinant human bone morphogenetic protein-2
Morbidity
Transplants
Bone and Bones
Wounds and Injuries
Infection
Neoplasms

ASJC Scopus subject areas

  • Surgery

Cite this

Use of recombinant human bone morphogenetic protein 2 for mandible reconstruction. / Desai, Shaun; Sclaroff, Alan; Nussenbaum, Brian.

In: JAMA Facial Plastic Surgery, Vol. 15, No. 3, 05.2013, p. 204-209.

Research output: Contribution to journalArticle

Desai, Shaun ; Sclaroff, Alan ; Nussenbaum, Brian. / Use of recombinant human bone morphogenetic protein 2 for mandible reconstruction. In: JAMA Facial Plastic Surgery. 2013 ; Vol. 15, No. 3. pp. 204-209.
@article{b95e810434c341c3ae56aded122f5386,
title = "Use of recombinant human bone morphogenetic protein 2 for mandible reconstruction",
abstract = "Background: Microvascular osseous free tissue transfer is the standard of care for reconstructing significant mandibulectomy defects; however, this procedure can carry a significant rate of morbidity. Objectives: To describe the use of recombinant human bone morphogenetic protein 2 (rhBMP-2) as an option for segmental or near-complete rim mandibulectomy defects in a select group of patients, precluding the need for free tissue transfer. Methods: A retrospective review was performed of 6 patients who had undergone repair of a mandible defect using rhBMP-2 with beta-tricalcium phosphate matrix or a cadaveric bone graft at a single tertiary care institution. The defects resulted from resection of benign neoplasms or from previous trauma. Reconstruction success was defined as no hardware problems, healing without infection, no need for further surgical procedures, and imaging evidence of healing and union without resorption. The median follow-up period was 37.5 months (range, 12-51 months). Results: Five of 6 patients underwent successful restoration of the mandibulectomy defect. One patient with a compromised immune system developed a significant postoperative wound infection requiring further reconstructive surgery. Conclusion: The use of an rhBMP-2-based reconstructive approach is a feasible option for segmental or nearcomplete rim mandibulectomy defects in a select group of patients. Level of Evidence: 4.",
author = "Shaun Desai and Alan Sclaroff and Brian Nussenbaum",
year = "2013",
month = "5",
doi = "10.1001/jamafacial.2013.650",
language = "English (US)",
volume = "15",
pages = "204--209",
journal = "JAMA Facial Plastic Surgery",
issn = "2168-6076",
publisher = "American Medical Association",
number = "3",

}

TY - JOUR

T1 - Use of recombinant human bone morphogenetic protein 2 for mandible reconstruction

AU - Desai, Shaun

AU - Sclaroff, Alan

AU - Nussenbaum, Brian

PY - 2013/5

Y1 - 2013/5

N2 - Background: Microvascular osseous free tissue transfer is the standard of care for reconstructing significant mandibulectomy defects; however, this procedure can carry a significant rate of morbidity. Objectives: To describe the use of recombinant human bone morphogenetic protein 2 (rhBMP-2) as an option for segmental or near-complete rim mandibulectomy defects in a select group of patients, precluding the need for free tissue transfer. Methods: A retrospective review was performed of 6 patients who had undergone repair of a mandible defect using rhBMP-2 with beta-tricalcium phosphate matrix or a cadaveric bone graft at a single tertiary care institution. The defects resulted from resection of benign neoplasms or from previous trauma. Reconstruction success was defined as no hardware problems, healing without infection, no need for further surgical procedures, and imaging evidence of healing and union without resorption. The median follow-up period was 37.5 months (range, 12-51 months). Results: Five of 6 patients underwent successful restoration of the mandibulectomy defect. One patient with a compromised immune system developed a significant postoperative wound infection requiring further reconstructive surgery. Conclusion: The use of an rhBMP-2-based reconstructive approach is a feasible option for segmental or nearcomplete rim mandibulectomy defects in a select group of patients. Level of Evidence: 4.

AB - Background: Microvascular osseous free tissue transfer is the standard of care for reconstructing significant mandibulectomy defects; however, this procedure can carry a significant rate of morbidity. Objectives: To describe the use of recombinant human bone morphogenetic protein 2 (rhBMP-2) as an option for segmental or near-complete rim mandibulectomy defects in a select group of patients, precluding the need for free tissue transfer. Methods: A retrospective review was performed of 6 patients who had undergone repair of a mandible defect using rhBMP-2 with beta-tricalcium phosphate matrix or a cadaveric bone graft at a single tertiary care institution. The defects resulted from resection of benign neoplasms or from previous trauma. Reconstruction success was defined as no hardware problems, healing without infection, no need for further surgical procedures, and imaging evidence of healing and union without resorption. The median follow-up period was 37.5 months (range, 12-51 months). Results: Five of 6 patients underwent successful restoration of the mandibulectomy defect. One patient with a compromised immune system developed a significant postoperative wound infection requiring further reconstructive surgery. Conclusion: The use of an rhBMP-2-based reconstructive approach is a feasible option for segmental or nearcomplete rim mandibulectomy defects in a select group of patients. Level of Evidence: 4.

UR - http://www.scopus.com/inward/record.url?scp=84880980622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880980622&partnerID=8YFLogxK

U2 - 10.1001/jamafacial.2013.650

DO - 10.1001/jamafacial.2013.650

M3 - Article

VL - 15

SP - 204

EP - 209

JO - JAMA Facial Plastic Surgery

JF - JAMA Facial Plastic Surgery

SN - 2168-6076

IS - 3

ER -